Clinical Trial Update: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

View source ↗

Summary

This document reports on a prospective, non-interventional observational study evaluating isatuximab in patients with relapsed and/or refractory multiple myelom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma | Status: ACTIVE_NOT_RECRUITING